# Salmon Peptide Fraction: Safety and Cardiometabolic Health

> **NCT05025462** · NA · COMPLETED · sponsor: **Laval University** · enrollment: 53 (actual)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DIETARY_SUPPLEMENT:** Supplement dose 15g/d
- **DIETARY_SUPPLEMENT:** Supplement dose 7.5g/d

## Key facts

- **NCT ID:** NCT05025462
- **Lead sponsor:** Laval University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-01
- **Primary completion:** 2023-07-26
- **Final completion:** 2023-07-26
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05025462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05025462, "Salmon Peptide Fraction: Safety and Cardiometabolic Health". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05025462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*